Myriad possesses the deepest diagnostic pipeline across the disease spectrum, including clinical tests in areas of unmet medical need such as autoimmune diseases, dermatology, neuroscience, oncology, urology and women’s health. Myriad’s research investment totals up to $358 million over the past five years.

Stage 1 DISCOVERY

  • myPath ® Bipolar
  • myPath ® Endometriosis